Reveal Genomics

Reveal Genomics is a private, commercial-stage diagnostics company focused on redefining precision oncology through integrated genomic and clinical data analysis. The company has successfully launched HER2DX®, its first proprietary test for HER2+ breast cancer treatment stratification, positioning it as a revenue-generating entity. Backed by a strong scientific founding team and public grant funding from Spanish and EU programs, Reveal Genomics is building a platform to develop further complex, interpretable diagnostic tests. Its near-term strategy involves commercial expansion of HER2DX® and leveraging its platform for new assay development.

Integrated analysis platform combining complex genomic data (e.g., from NGS) with comprehensive clinical information to develop multivariate diagnostic signatures for precision oncology.

HER2DX® competes in the breast cancer genomic assay space against established multi-gene tests like Oncotype DX and MammaPrint, though it specifically targets the HER2+ niche. It also faces potential competition from large reference laboratories and other diagnostics companies developing novel biomarkers for treatment stratification in oncology.